Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Cowen and Company

BioCentury | Nov 17, 2023
Politics, Policy & Law

IRA’s unintended consequences include harm to rare disease patients

Advocates, biopharma companies push Congress to revise the law to reduce barriers to orphan drug development
BioCentury | Oct 26, 2021
Guest Commentary

Biopharma companies are still undervaluing external innovation

The case for being bolder and taking risks on early clinical deals
BioCentury | Feb 19, 2021
Product Development

First-time CEOs must stop doing what made them successful: Guest Commentary

Practical advice for first-time biotech CEOs
BioCentury | Mar 20, 2020
Product Development

Promoting more effective biotech boards

Guest Commentary: Biotech boards would be higher functioning if they embraced a culture of debate
BioCentury | Mar 11, 2019
Clinical News

Axovant reports first clinical gene therapy data

BioCentury | Aug 18, 2008
Company News

Nanogen, Elitech deal

BioCentury | Jun 23, 2008
Company News

Biogen Idec biopharmaceuticals news

Items per page:
1 - 7 of 7
Help Center
Username
Request a Demo
Request Training
Ask a Question